Inhibrx Biosciences, Inc. (INBX) stock intrinsic value fair value estimate & owner earnings analysis

Inhibrx Biosciences is a clinical-stage cancer drug developer based in La Jolla, California. It has no product sales (about $1.3 million of collaboration revenue in 2025) and is spending roughly $125-135 million a year. Everything rests on one drug, ozekibart (INBRX-109), a four-armed antibody that triggers cancer-cell death through the DR5 receptor. A secondary program, INBRX-106, and early trials in Ewing sarcoma and colorectal cancer sit behind it. What is real today: in October 2025 the ChonDRAgon trial (200+ patients, randomized, placebo-controlled) in unresectable or metastatic conventional chondrosarcoma met its main goal. Median time before the cancer progressed was 5.52 months on ozekibart versus 2.66 months on placebo (hazard ratio 0.479, p<0.0001). The drug has FDA Fast Track and orphan designations, there is no approved drug therapy for this cancer, and the company said it planned to file for FDA approval early in the second quarter of 2026. Patents run to between 2036 and 2043. Against that: one liver-related death occurred early in the trial, liver enzyme events were more frequent on the drug (11.8% vs 4.5%), the benefit is measured in months of delayed progression rather than survival, and the disease is rare (about 1,400 US cases a year across all types and stages). Earnings: owner earnings (operating cash flow less working-capital swings, stock compensation and capital spending) have been negative every year: about -$20.38 per share in 2023, -$20.83 in 2024 (inflated by stock-compensation acceleration around the 2024 spin-off) and -$8.71 in 2025. The loss per share narrowed in 2025, but that reflects the end of heavy trial spending and one-time 2024 items, not a business turning profitable. Early 2026 shows cash use of about $68 million in the first half. Because the business has no earnings level to normalize, no anchor is drawn from history; each case is built from named events instead. Year one of every case assumes cash burn continues at roughly the 2025-2026 pace, not an improvement. Debt: the company has a secured term loan with Oxford Finance: $100 million drawn in January 2025 plus $75 million more in March 2026. It costs about 10% (5.61% plus SOFR, floored at 4.34%), is interest-only until February 2028, then amortizes to a January 1, 2030 maturity, with a 9% final fee (about $16 million in total). The lender requires at least $40 million of liquidity at all times, and a material adverse change can trigger prepayment. Total owed is roughly $191 million against $133 million of cash at June 30, 2026, so net debt is about $57 million. We add about $15 million because the loan will cost well above 6% for several years. Cash above the $40 million covenant floor is roughly $93 million, about 16 months of current burn, so new capital or an approval-driven improvement is needed around late 2027. Bear case: -$3.66 per share. The FDA approval is delayed or refused (the liver-safety record and the survival-free benefit are the named risks) and no other program yields value; nothing else is evidenced, so the operating business is worth $0. The company owes about $191 million against $133 million of cash, so it appears to owe more than it is worth, by about $57 million, or roughly $3.66 per share. Shareholders' losses are in practice capped at their investment, but we state the shortfall plainly. Base case: $2.62 per share. Ozekibart is approved for chondrosarcoma in the United States in the first half of 2027 and is launched by a small commercial team. This uses the trial result, Fast Track, orphan status and the 1,400-case incidence; it is not a management target. We assume treated patients rise to about 350 a year at roughly $200,000 per treatment course, giving about $70 million of annual sales by 2030 (a judgement, since price and share are not contracted or filed). Costs are held to about $40-50 million a year, so business cash flow is about -$33 million in the last quarter of 2026, -$39 million in 2027, -$8 million in 2028, then +$13 million in 2029 and about +$24 million a year from 2030 to 2042, when patents and orphan protection roll off; nothing is assumed afterward. Business value is about $113 million; debt and financing costs are about $72 million net of cash; the difference is about $41 million, or $2.62 per share. Cash flow is below the interest bill through 2028, so roughly $25-30 million of new capital would be needed; we assume it is raised at fair value. Left out: Ewing sarcoma and colorectal indications, INBRX-106, sales outside the United States and any partnering, because none has a trial result, contract or filing behind it yet. Bull case: $24.95 per share. Approval comes early in 2027 and the drug reaches about 500 patients a year at about $240,000 a course (about $120 million of sales by 2030), costs stay near $45-50 million, and the business generates about $65 million a year from 2030 to 2042. Business value is about $463 million against about $72 million of net debt and financing cost, leaving about $391 million. This case does not require the Ewing sarcoma indication, which management has said it may discuss with the FDA in the second half of 2026, because that is not secured. What would make this wrong: a refusal or a safety-driven label restriction would move the shares toward the bear case; a price or patient count far above ours would move it toward the bull case; and a large equity raise at a low price would reduce per-share value. Judgements that mattered: stock compensation is treated as a real cost, and interest is added back to measure the business before its lender and then the debt is subtracted, not counted twice. The 2023-2024 history is carve-out data from before the spin-off and is not a guide to the current business. Sales figures for the cases are our estimates, not filing data, and could not be reconciled to any company disclosure.